A Phase 3 interventional study of Investigational Seasonal Affective Disorder (SAD) Drug in Seasonal Affective Disorder (SAD), sponsored by GlaxoSmithKline. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-04.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
A Placebo Controlled Study Evaluating The Effectivess Of Medication In Preventing Seasonal Affective Disorder
584 studies on the registry are indexed under Mood Disorders; 117 are open to participants now.
Browse Mood Disorders studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.)
Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.)
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline